Indefinite Delivery Contract 36E79725D0032
Award Date
9/15/25
Last Date to Order
9/14/26
Federal Agency
National Acquisition Center
Awardee
Pfizer Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc. to provide an uninterrupted supply of Bevacizumab (ZIRABEV) for the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract has a 1-year base period with four 1-year option periods, for a total potential period of performance through August 12, 2025. The contract value has a ceiling of...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $66,935,445.85 and a period of performance from October 8, 2020 to October 7, 2025, with four one-year option periods. The purpose of this IDC is to provide the U.S. federal government with a source for Epoetin vials, a critical pharmaceutical product. As one of the world's largest pharmaceutical companies, Pfizer...
The Department of Veterans Affairs National Acquisition Center has awarded a single-award Indefinite Delivery Contract (IDC) to Organon LLC for Infliximab Injection 100 mg/vial. The $119,538,562.32 contract has a base period of one year and four one-year option periods, running from September 1, 2023 through August 31, 2025. This IDC will provide an uninterrupted supply of the pharmaceutical product to the VA, Bureau of Prisons, and Indian Health Service through the VA's Pharmaceutical Prime...
The federal contract IDV award is a $7.31 billion Federal Supply Schedule contract with the Department of Veterans Affairs (VA) awarded to Pfizer Inc., a large pharmaceutical manufacturer. The contract covers a wide range of pharmaceutical products including controlled substances, antibiotics, pain medications, anti-nausea drugs, hormone treatments, and emergency medical interventions. This IDV contract allows Pfizer to deliver critical healthcare supplies across various government agencies such...
This federal contract IDV award is for the provision of Bevacizumab injections to support multiple federal healthcare organizations, including the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract was awarded to Pfizer Inc. as the single prime contractor, with a ceiling value of $46,893,140.00 and a total ordering period from August 13, 2025 to August 12, 2026, with four additional one-year...
The Department of Veterans Affairs (VA) National Acquisition Center has awarded Organon LLC a single-award Indefinite Delivery Contract (IDC) valued at $325,063,436.44 to provide Adalimumab pen and syringe kits. The contract has a base year of March 9, 2024 to March 8, 2025, with four one-year option periods, for a total potential period of performance through March 8, 2026. The IDC will support the VA's Pharmaceutical Prime Vendor program, as well as provide Adalimumab products to the Bureau of...
The federal contract IDV is a single-award Indefinite Delivery Contract (IDC) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Sandoz Inc., a global leader in generic pharmaceuticals and biosimilars. The contract, valued at a ceiling of $26,399,360.75, is for the supply of pegfilgrastim injectables to the VA, Bureau of Prisons, and Indian Health Service. The contract has a base period of one year and four one-year option periods, with an estimated annual...
This federal contract IDV award is for the supply of ranibizumab ophthalmic injections to the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The single-award indefinite delivery contract, valued at $11,392,063.40, was issued by the VA National Acquisition Center to the prime contractor Biogen U.S. Corporation, a for-profit pharmaceutical manufacturer. The contract has a performance period from December 23, 2023, through December 22, 2025, with four...
The National Acquisition Center, a civilian agency of the U.S. Department of Veterans Affairs, awarded a single-award Indefinite Delivery Contract (IDC) to TG Therapeutics Inc., a for-profit pharmaceutical manufacturer, to provide ublituximab-XIIY 150mg/6ml injection, an anti-CD20 antibody, for a 1-year base period and four 1-year option periods through June 16, 2026. The $186,776,520 IDC was awarded on June 17, 2024 with the intent to list the awarded product as the preferred agent on the VA...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian federal agency, to Avkare LLC, a pharmaceutical and medical supply company, to provide a wide range of pharmaceutical products to the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract has a total ceiling value of $12,991,472.85 and a period of performance from March 16, 2020 to March 15, 2025. It was awarded as a...